These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1246 related articles for article (PubMed ID: 25965710)

  • 21. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial.
    Muhlestein JB; Lappé DL; Lima JA; Rosen BD; May HT; Knight S; Bluemke DA; Towner SR; Le V; Bair TL; Vavere AL; Anderson JL
    JAMA; 2014 Dec; 312(21):2234-43. PubMed ID: 25402757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.
    White WB; Kupfer S; Zannad F; Mehta CR; Wilson CA; Lei L; Bakris GL; Nissen SE; Cushman WC; Heller SR; Bergenstal RM; Fleck PR; Cannon CP;
    Diabetes Care; 2016 Jul; 39(7):1267-73. PubMed ID: 27289121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.
    Nicholls SJ; Lincoff AM; Barter PJ; Brewer HB; Fox KA; Gibson CM; Grainger C; Menon V; Montalescot G; Rader D; Tall AR; McErlean E; Riesmeyer J; Vangerow B; Ruotolo G; Weerakkody GJ; Nissen SE
    Am Heart J; 2015 Dec; 170(6):1061-9. PubMed ID: 26678626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of lixisenatide in elderly (≥65 years old) and very elderly (≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme.
    Raccah D; Miossec P; Esposito V; Niemoeller E; Cho M; Gerich J
    Diabetes Metab Res Rev; 2015 Feb; 31(2):204-11. PubMed ID: 25115916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome.
    O'Donoghue ML; Braunwald E; White HD; Serruys P; Steg PG; Hochman J; Maggioni AP; Bode C; Weaver D; Johnson JL; Cicconetti G; Lukas MA; Tarka E; Cannon CP
    Am Heart J; 2011 Oct; 162(4):613-619.e1. PubMed ID: 21982651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes trial.
    Clemmensen P; Roe MT; Hochman JS; Cyr DD; Neely ML; McGuire DK; Cornel JH; Huber K; Zamoryakhin D; White HD; Armstrong PW; Fox KA; Prabhakaran D; Ohman EM;
    Am Heart J; 2015 Oct; 170(4):695-705.e5. PubMed ID: 26386793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
    Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
    J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of dalcetrapib in patients with a recent acute coronary syndrome.
    Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Mundl H; Nicholls SJ; Shah PK; Tardif JC; Wright RS;
    N Engl J Med; 2012 Nov; 367(22):2089-99. PubMed ID: 23126252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus.
    Elharram M; Sharma A; White W; Bakris G; Rossignol P; Mehta C; Ferreira JP; Zannad F
    Am Heart J; 2020 Nov; 229():40-51. PubMed ID: 32916607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
    Knopp RH; d'Emden M; Smilde JG; Pocock SJ
    Diabetes Care; 2006 Jul; 29(7):1478-85. PubMed ID: 16801565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
    Held C; Asenblad N; Bassand JP; Becker RC; Cannon CP; Claeys MJ; Harrington RA; Horrow J; Husted S; James SK; Mahaffey KW; Nicolau JC; Scirica BM; Storey RF; Vintila M; Ycas J; Wallentin L
    J Am Coll Cardiol; 2011 Feb; 57(6):672-84. PubMed ID: 21194870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical burden of type 2 diabetes in patients with acute coronary syndromes: prognosis and implications for short- and long-term management.
    Katz P; Leiter LA; Mellbin L; Rydén L
    Diab Vasc Dis Res; 2014 Nov; 11(6):395-409. PubMed ID: 25187508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial.
    Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Skene A; McCabe CH; Braunwald E;
    Am Heart J; 2006 Jun; 151(6):1186.e1-9. PubMed ID: 16781216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome.
    Eisenberg MJ; Windle SB; Roy N; Old W; Grondin FR; Bata I; Iskander A; Lauzon C; Srivastava N; Clarke A; Cassavar D; Dion D; Haught H; Mehta SR; Baril JF; Lambert C; Madan M; Abramson BL; Dehghani P;
    Circulation; 2016 Jan; 133(1):21-30. PubMed ID: 26553744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of a multifaceted intervention on use of evidence-based therapies in patients with acute coronary syndromes in Brazil: the BRIDGE-ACS randomized trial.
    Berwanger O; Guimarães HP; Laranjeira LN; Cavalcanti AB; Kodama AA; Zazula AD; Santucci EV; Victor E; Tenuta M; Carvalho V; Mira VL; Pieper KS; Weber B; Mota LH; Peterson ED; Lopes RD;
    JAMA; 2012 May; 307(19):2041-9. PubMed ID: 22665103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
    Zannad F; Cannon CP; Cushman WC; Bakris GL; Menon V; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Lam H; White WB;
    Lancet; 2015 May; 385(9982):2067-76. PubMed ID: 25765696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lixisenatide for type 2 diabetes mellitus.
    Christensen M; Knop FK; Vilsbøll T; Holst JJ
    Expert Opin Investig Drugs; 2011 Apr; 20(4):549-57. PubMed ID: 21391833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.
    Cannon CP; Giugliano RP; Blazing MA; Harrington RA; Peterson JL; Sisk CM; Strony J; Musliner TA; McCabe CH; Veltri E; Braunwald E; Califf RM;
    Am Heart J; 2008 Nov; 156(5):826-32. PubMed ID: 19061694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder.
    White WB; Grady D; Giudice LC; Berry SM; Zborowski J; Snabes MC
    Am Heart J; 2012 Jan; 163(1):27-32. PubMed ID: 22172433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 63.